The Medicines and Healthcare products Regulatory Agency (MHRA) is strengthening its collaboration with the US Food and Drug Administration (FDA) to accelerate patient access to safe and innovative medical technologies in both the United Kingdom and the United States.

This enhanced partnership, part of the broader US–UK pharmaceutical collaboration, aims to streamline regulatory pathways for medical devices while maintaining the highest safety standards. It also complements recent efforts to remove tariffs on UK medicine exports and encourage earlier access to advanced treatments.

Under the initiative, the MHRA and FDA will explore opportunities to align regulatory processes, including potential mutual recognition mechanisms—allowing parts of each other’s approval systems to be recognised. This approach is expected to reduce duplication for manufacturers and speed up approvals, enabling faster access to cutting-edge diagnostics, devices, and therapies.

Despite closer alignment, both regulators will retain independent decision-making authority, ensuring rigorous standards for safety, quality, and effectiveness.

UK Health Innovation and Safety Minister Dr Zubir Ahmed said the collaboration would enable innovative technologies to reach NHS patients more quickly without compromising safety, reinforcing the UK’s ambition to be a global hub for health innovation.

UK Science Minister Lord Vallance highlighted the strength of the country’s MedTech sector, which employs over 195,000 people, adding that the partnership will further enhance the UK’s leadership in developing transformative healthcare technologies.

MHRA Chief Executive Lawrence Tallon described the agreement as a significant step in advancing UK innovation, noting that closer ties with the FDA will improve efficiency and help bring new technologies to patients faster.

Industry leaders also welcomed the move. ABHI said the collaboration would reduce regulatory duplication and provide clearer pathways for businesses, while techUK noted that stronger alignment would particularly benefit innovators and small and medium enterprises by simplifying market access.

Technical discussions between the MHRA and FDA will continue in the coming months to identify areas for deeper alignment and assess the feasibility of mutual recognition frameworks.

The initiative underscores the UK’s broader strategy to strengthen global regulatory partnerships, enhance life sciences innovation, and ensure timely patient access to high-quality medical technologies.